On Tuesday, the agency gave the green light for Ozempic to help protect kidney function in people with diabetes and Zepbound as the first-ever drug treatment for sleep apnea in people with obesity.

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro ... as Alzheimer's disease (AD) treatment Kisunla, ulcerative ...

Zepbound is an injectable prescription medication created to help adults with obesity and weight-related problems, including obstructive sleep apnea. OSA causes airway collapses during sleep and ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls ... packages for our investment conferences and advertising on our websites and newsletters.

CMS confirms that Medicare Part D plans can cover Zepbound for the sleep disorder Medicare drug plans can now cover Eli Lilly & Co.'s obesity drug Zepbound as a treatment for obstructive sleep ...